NEW YORK –(ENEWSPF)–January 28, 2015. American molecular diagnostic company Myriad Genetics has settled litigation seeking to enforce patents on two genes associated with hereditary breast and ovarian cancer. The company has agreed to dismiss its claims against four laboratories and is discussing settlements with the remaining laboratories.
“Patients who need access to life-changing genetic testing should not be caught in the legal battle that Myriad Genetics has unfairly waged against competing laboratories, nor should scientists…
